1.17

1.68% -0.02

After Hours: 1.16 -0.01 -0.85%

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $1.17, with a volume of 842.33K. It is down -1.68% in the last 24 hours and up +23.90% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$1.19

Open:

$1.18

24h Volume:

842.33K

Relative Volume:

0.35

Market Cap:

$267.18M

Revenue:

$8.95M

Net Income/Loss:

$-21.49M

P/E Ratio:

-9.75

EPS:

-0.12

Net Cash Flow:

$-29.24M

1W Performance:

+14.71%

1M Performance:

+23.90%

6M Performance:

+73.08%

1Y Performance:

+28.81%

1-Day Range:

$1.15

$1.19

1-Week Range:

$1.0294

$1.31

52-Week Range:

$0.3651

$1.31

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1159)

Industry

Biotechnology (645)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2025-03-10

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	1.17	292.30M	8.95M	-21.49M	-29.24M	-0.12
VRTX Vertex Pharmaceuticals Inc	397.46	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	598.16	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	467.55	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	663.73	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.97	37.96B	3.81B	-644.79M	-669.77M	-6.24

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Aug 20, 2025

Published on: 2025-08-21 02:00:17 - kangso.co.kr

Aug 20, 2025

Aug 18, 2025

How to track smart money flows in Lineage Cell Therapeutics Inc.Weekly Earnings Recap & Community Verified Trade Signals - Newser

Aug 18, 2025

Trend Reversal Possible in Lineage Cell Therapeutics Inc. Charts IndicateAnalyst Upgrade & AI Enhanced Trade Execution Alerts - beatles.ru

Aug 18, 2025

Aug 17, 2025

Will breakout in Lineage Cell Therapeutics Inc. lead to full recoveryJuly 2025 Technicals & Accurate Intraday Trading Signals - Newser

Aug 17, 2025

Heatmap analysis for Lineage Cell Therapeutics Inc. and competitorsBear Alert & AI Powered Buy and Sell Recommendations - Newser

Aug 17, 2025

Aug 16, 2025

Is Lineage Cell Therapeutics Inc. stock a value trapWeekly Volume Report & Weekly Momentum Picks - thegnnews.com

Aug 16, 2025

Published on: 2025-08-17 09:06:42 - mustnews.co.kr

Aug 16, 2025

How to recover losses in Lineage Cell Therapeutics Inc. stockQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser

Aug 16, 2025

Combining price and volume data for Lineage Cell Therapeutics Inc.2025 Top Gainers & Technical Confirmation Trade Alerts - Newser

Aug 16, 2025

What does recent volatility data suggest for Lineage Cell Therapeutics Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - Newser

Aug 16, 2025

Aug 15, 2025

Relative strength of Lineage Cell Therapeutics Inc. in sector analysisGDP Growth & Safe Entry Trade Reports - Newser

Aug 15, 2025

Applying Wyckoff theory to Lineage Cell Therapeutics Inc. stockWeekly Stock Recap & Reliable Intraday Trade Alerts - Newser

Aug 15, 2025

What data driven models say about Lineage Cell Therapeutics Inc.’s futureJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - Newser

Aug 15, 2025

Lineage Cell (LCTX) Surges 25% Intraday: Algorithmic Frenzy or Retail Rally? - AInvest

Aug 15, 2025

Behind Lineage Cell Therapeutics Inc’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com

Aug 15, 2025

Lineage Cell Surges 24.5% on Biotech Sector Rally: What's Fueling the Momentum? - AInvest

Aug 15, 2025

Lineage Cell (LCTX.A) Surges 14.7% — Was It Driven by Order Flow or Sector Momentum? - AInvest

Aug 15, 2025

Risk adjusted return profile for Lineage Cell Therapeutics Inc. analyzedTrade Exit Report & Community Consensus Picks - Newser

Aug 15, 2025

Exit strategy if you’re trapped in Lineage Cell Therapeutics Inc.Take Profit & Real-Time Chart Breakout Alerts - Newser

Aug 15, 2025

Aug 14, 2025

Promising Developments and Strong Financial Position Support Buy Rating for Lineage Cell Therapeutics - TipRanks

Aug 14, 2025

Craig-Hallum Keeps Their Buy Rating on Lineage Therap (LCTX) - The Globe and Mail

Aug 14, 2025

Will Lineage Cell Therapeutics Inc. Benefit From Broader Market BounceNew Guidance & Weekly High Return Opportunities - sundaytimes.kr

Aug 14, 2025

Detecting support and resistance levels for Lineage Cell Therapeutics Inc.July 2025 Volume & Free Community Supported Trade Ideas - Newser

Aug 14, 2025

Aug 13, 2025

How to build a dashboard for Lineage Cell Therapeutics Inc. stock2025 Price Momentum & Low Risk Entry Point Guides - Newser

Aug 13, 2025

Is Lineage Cell Therapeutics Inc. stock ready for a breakout2025 Top Decliners & Weekly High Potential Stock Alerts - Newser

Aug 13, 2025

Analyzing recovery setups for Lineage Cell Therapeutics Inc. investors2025 Market Overview & Precise Buy Zone Tips - Newser

Aug 13, 2025

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2025 Earnings Call Transcript - MSN

Aug 13, 2025

Lineage Cell Therapeutics: Strong Financials and Promising Clinical Data Drive Buy Rating - TipRanks

Aug 13, 2025

Lineage Cell Therapeutics Reports Q2 2025 Progress and Challenges - MSN

Aug 13, 2025

Lineage Cell: Q2 Earnings Snapshot - Stamford Advocate

Aug 13, 2025

Can a trend reversal in Lineage Cell Therapeutics Inc. lead to recoveryPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser

Aug 13, 2025

Lineage Cell Therapeutics (LCTX): Strategic Partnerships and Platform Expansion as Catalysts for Value Creation - AInvest

Aug 13, 2025